Elrelesertib
Based on 13 publication(s) in Google Scholar
Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer.
For research use only. We do not sell to patients.
- Purity : 99.22%
- CAS No.: 2089288-03-7
- Formula: C27H32FN5O2
- Molecular Weight:477.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Elrelesertib
More- Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]
- Nat Nanotechnol. 2021 Jul;16(7):830-839. [Abstract]
- Sci Adv. 2026 May 22;12(21):eaec2231. [Abstract]
- EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]
- Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):957-971. [Abstract]
- J Med Chem. 2024 May 9;67(9):7620-7634. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- CNS Neurosci Ther. 2024 Apr;30(4):e14696. [Abstract]
- Cancers (Basel). 2026 Jul 23;18(15):2381. [Abstract]
- Shock. 2023 Jul 1;60(1):100-109. [Abstract]
- EANM Innovation. 2026 May 19;3:100274.
- University of Califomia San Francisco. 2026.
- bioRxiv. 2025 Jul 31.
-
WB
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
IP
-
Others
Biological Activity
Description
IC50 & Target
[1]|
ATM 0.78 nM (IC50) |
Chk2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H2228 | IC50 |
0.78 nM
|
Inhibition of cellular ATM activity in human NCI-H2228 p53 mutant lung cancer cells, measured via high-content immunofluorescence imaging assay of DDR biomarkers with 1-hour pre-incubation and analysis up to 48 hours post-irradiation.
Inhibition of cellular ATM activity in human NCI-H2228 p53 mutant lung cancer cells, measured via high-content immunofluorescence imaging assay of DDR biomarkers with 1-hour pre-incubation and analysis up to 48 hours post-irradiation.
|
29938225 |
| MCF7 | IC50 |
16.143 μM
|
Reduction in cell viability against human breast cancer MCF-7 cells incubated for 12 hrs by WST-1 assay.
Reduction in cell viability against human breast cancer MCF-7 cells incubated for 12 hrs by WST-1 assay.
|
39681282 |
| MDA-MB-231 | IC50 |
5.524 μM
|
Reduction in cell viability against human breast cancer MDA-MB-231 cells incubated for 12 hrs by WST-1 assay.
Reduction in cell viability against human breast cancer MDA-MB-231 cells incubated for 12 hrs by WST-1 assay.
|
39681282 |
| MCF7 | IC50 |
10.685 μM
|
Reduction in cell viability against human breast cancer MCF-7 cells incubated for 24 hrs by WST-1 assay.
Reduction in cell viability against human breast cancer MCF-7 cells incubated for 24 hrs by WST-1 assay.
|
39681282 |
| MDA-MB-231 | IC50 |
2.563 μM
|
Reduction in cell viability against human breast cancer MDA-MB-231 cells incubated for 24 hrs by WST-1 assay.
Reduction in cell viability against human breast cancer MDA-MB-231 cells incubated for 24 hrs by WST-1 assay.
|
39681282 |
In Vitro
Elrelesertib (AZD1390) (3-300 nM; 1 h pre-incubation, 4 h post-irradiation) dose-dependently inhibits ATM target engagement in LN18 p53 mutant GBM cells, with strong inhibition of phospho-ATM Ser1981 observed at 3 nM[1].
Elrelesertib (10-100 nM; 1 h pre-incubation, 1 h/6 h post-irradiation, 6 h post-washout) dose-dependently modulates ATM pathway activity in NCI-H2228 p53 mutant lung cancer cells, with pathway reactivation observed 6 hours after washout[1].
Elrelesertib (0.125-1250 nM; 1 h pre-incubation, 1/6/24/48 h post-irradiation) inhibits DDR biomarkers in NCI-H2228 p53G12C mutant lung cancer cells, with an XC50 of 2.7 nM for discrete phospho-ATM foci, and dose-dependently increases micronuclei formation when combined with radiation[1].
Elrelesertib (10 nM; 1 h pre-incubation, 12-14 days post-irradiation) potently radiosensitizes p53 mutant GBM and lung cancer cell lines more effectively than p53 wild-type cell lines in clonogenic survival assays[1].
Elrelesertib (10 nM; 1 h pre-incubation, 5 days post-irradiation) potently radiosensitizes p53 mutant GBM cell lines more effectively than p53 wild-type GBM cell lines in a high-throughput Live/Dead antiproliferation assay[1].
Elrelesertib (0.125-100 nM; 1 h pre-incubation, 24/48 h post-irradiation) in combination with radiation causes dose-dependent G2 phase accumulation and apoptosis (sub-G1 population) in NCI-H2228 p53 mutant lung cancer cells[1].
Elrelesertib (0.2-2 nM; 24 h) completely abrogates clonogenic capacity in MCF-7, MDA-MB-231, and RPE-1 cells[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently inhibits proliferation in MCF-7, MDA-MB-231, and RPE-1 cells over a 24-h period, with significant effects at higher concentrations[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently elevates intracellular ROS levels in MCF-7, MDA-MB-231, and RPE-1 cells after 24 h of treatment[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently reduces mitochondrial membrane potential in MCF-7, MDA-MB-231, and RPE-1 cells after 24 h of treatment[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently induces DNA damage in MCF-7, MDA-MB-231, and RPE-1 cells after 24 h of treatment, as measured by increased comet % Tail DNA and tail length[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently arrests MCF-7, MDA-MB-231, and RPE-1 cells in the G2-M phase of the cell cycle after 24 h of treatment[3].
Elrelesertib (0.2-5 μM; 24 h) dose-dependently induces apoptosis and necrosis in MCF-7, MDA-MB-231, and RPE-1 cells after 24 h of treatment, with significant increases in apoptotic cell percentages in breast cancer cell lines[3].
Elrelesertib (0.2-5 μM) dose-dependently inhibits ATM phosphorylation (reduces p-ATM levels without altering total ATM) and modulates apoptosis-related protein expression (increases PARP, Beclin-1, BAX; decreases Bcl-2) in MCF-7 and MDA-MB-231 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LN18 glioblastoma (GBM) cells (p53 mutant)
-
Concentration:3, 10, 300 nM
-
Incubation Time:1 h (pre-incubation); 4 h (post-irradiation)
-
Result:Dose-dependently inhibited ATM autophosphorylation (phospho-ATM Ser1981) at 4 hours post-treatment, with strong inhibition observed at 3 nM.
Did not affect phosphorylation of non-ATM pathway markers including KAP1, CDK1, or p53.
-
Cell Line:NCI-H2228 lung cancer cells (p53 mutant)
-
Concentration:10, 100 nM
-
Incubation Time:1 h (pre-incubation); 1, 6 h (post-irradiation); 6 h (post-washout)
-
Result:Dose-dependently inhibited phospho-KAP1 Ser824 and phospho-Chk2 Thr68 at 1 and 6 hours post-treatment.
Began to rise phospho-Chk2 levels at 6 hours after washout.
-
Cell Line:NCI-H2228 lung cancer cells (p53 mutant)
-
Concentration:0.125, 0.3125, 1, 3, 12.5, 31.25, 100, 300, 1250 nM
-
Incubation Time:1 h (pre-incubation); 1, 6, 24, 48 h (post-irradiation)
-
Result:Achieved XC50 values of 0.78 nM for inhibition of total nuclear phospho-ATM and γH2AX staining, and 2.7 nM for inhibition of discrete nuclear phospho-ATM foci.
Dose-dependently increased micronuclei formation when combined with radiation.
-
Cell Line:NCI-H2228 lung cancer cells (p53 mutant)
-
Concentration:0.125, 0.3125, 1, 3, 12.5, 31.25,100 nM
-
Incubation Time:1 h (pre-incubation); 24, 48 h (post-irradiation)
-
Result:Combined with 2 Gy IR, caused a dose-dependent increase in G2 phase accumulation at 24 hours.
Combined with 2 Gy IR, caused a dose-dependent increase in sub-G1 population at 48 hours, indicating induction of apoptosis.
-
Cell Line:GBM and lung cancer cell lines (LN18, T98G, NCI-H2228, A172, DDBRTG-05MG, U87MG)
-
Concentration:10 nM
-
Incubation Time:1 h (pre-incubation); 12-14 days (post-irradiation)
-
Result:Radiosensitized p53 mutant cell lines more potently than p53 wild-type lines.
-
Cell Line:GBM cell lines (LN18, T98G, HS683T, SW1088, SW1783, DDBRTG-05MG, CCF-STTG1, A172, U87-MG)
-
Concentration:10 nM
-
Incubation Time:1 h (pre-incubation); 5 days (post-irradiation)
-
Result:Radiosensitized p53 mutant cell lines more potently than p53 wild-type lines.
-
Cell Line:human breast cancer cell lines MCF-7, MDA-MB-231, human non-transformed epithelial cell line RPE-1
-
Concentration:0.2, 0.4, 0.6, 0.8, 1 μM (MDA-MB-231, RPE-1); 1, 2, 3, 4, 5 μM (MCF-7)
-
Incubation Time:24 h
-
Result:Caused a dose-dependent reduction in cell proliferation in all three cell lines over 24 h.
Induced significant effects at the highest three concentrations for each cell line compared to controls.
-
Cell Line:human breast cancer cell lines MCF-7, MDA-MB-231, human non-transformed epithelial cell line RPE-1
-
Concentration:0.2, 0.6, 1 μM (MDA-MB-231, RPE-1); 1, 3, 5 μM (MCF-7)
-
Incubation Time:24 h
-
Result:Caused a dose-dependent increase in the proportion of cells in the G2-M phase and a corresponding decrease in the S phase in all three cell lines compared to untreated controls.
Indicated cell cycle arrest at the G2-M checkpoint.
-
Cell Line:human breast cancer cell lines MCF-7, MDA-MB-231, human non-transformed epithelial cell line RPE-1
-
Concentration:0.2, 0.6, 1 μM (RPE-1); 0.2, 0.65, 1 μM (MDA-MB-231); 1, 3, 5 μM (MCF-7)
-
Incubation Time:24 h
-
Result:Caused a dose-dependent increase in early and late apoptotic cells, as well as necrotic cells, in all three cell lines compared to DMSO-treated controls.
Induced statistically significant increases in apoptotic cell percentage in breast cancer cell lines.
Parmacokinetics
| Species | Dose | Route | CL | Vss | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|
| Rat[1] | 10 mg/kg | p.o. | 16.3 mL/min/kg | 3.0 L/kg | 2.4 h | 74 % |
In Vivo
Elrelesertib (2-20 mg/kg; p.o.; single dose) inhibits IR-induced ATM pathway activation in a dose- and time-dependent manner and induces apoptosis in a mouse model of intracranial lung cancer brain metastasis, with free brain exposure correlating with pharmacodynamic activity[1].
Elrelesertib (5-15 mg/kg; p.o.; q.d; 5 days) combined with daily 2 Gy IR and TMZ provides additive tumor growth inhibition and survival benefit in a mouse model of intracranial lung cancer brain metastasis[1].
Elrelesertib (2-20 mg/kg; p.o.; q.d; 4 days) combined with daily 2.5 Gy IR provides dose-dependent tumor growth inhibition and survival benefit in a mouse model of lung cancer brain metastasis established via intracarotid artery injection[1].
Elrelesertib (5-20 mg/kg; p.o.; q.d) combined with stereotactic IR significantly improves survival in an immunocompetent mouse model of intracranial glioblastoma, with a dose-dependent efficacy response observed[1].
Elrelesertib (20 mg/kg; p.o.; q.d; 5 days) combined with daily 2 Gy IR produces robust tumor growth inhibition and survival benefit in a panel of subcutaneous glioblastoma PDX models, with p53 mutant models showing particularly strong responses[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunodeficient nude mice (6-8 weeks old)[1]
-
Dosage:5, 20 mg/kg
-
Administration:p.o.; q.d for 4 days; b.i.d for 4 days
-
Result:Showed marginal tumor growth inhibition (TGI) at 5 mg/kg q.d plus IR.
Produced superior TGI and significantly improved survival compared to IR alone at 20 mg/kg q.d or b.i.d plus IR.
Induced a statistically significant increase in the apoptotic biomarker cleaved caspase-3 (CC3) compared to IR alone.
-
Animal Model:Immunodeficient nude mice (6-8 weeks old)[1]
-
Dosage:5, 15 mg/kg
-
Administration:p.o.; q.d for 5 days
-
Result:The triplet combination of 15 mg/kg q.d, 2 Gy ×5 IR, and 25 mg/kg TMZ q.d was well-tolerated, provided additive TGI and survival benefit over the 15 mg/kg plus IR doublet arm.
-
Animal Model:Immunodeficient nude mice (6-8 weeks old)[1]
-
Dosage:2, 5, 20 mg/kg
-
Administration:p.o.; q.d for 4 days
-
Result:Produced dose-dependent TGI and survival benefit compared to IR alone.
Showed the most pronounced efficacy in reducing tumor growth and extending survival at 20 mg/kg dose.
-
Animal Model:C57 Black 6 mice[1]
-
Dosage:5, 20 mg/kg
-
Administration:p.o.; q.d for the duration of IR dosing
-
Result:Significantly improved survival compared to IR or Elrelesertib alone at 20 mg/kg q.d combined with two 5-Gy IR fractions.
Significantly improved survival compared to IR alone at 5 mg/kg q.d combined with ten 2-Gy IR fractions, though efficacy was reduced compared to the 20 mg/kg dose.
-
Animal Model:NMRI nude mice (female, 7-11 weeks old)[1]
-
Dosage:20 mg/kg
-
Administration:p.o.; q.d for 5 days
-
Result:Produced robust tumor growth inhibition and survival benefit across the PDX panel.
Showed particularly strong responses in p53 mutant models (ST108, ST112), while the least responsive model was p53 wild-type (ST2473).
Several p53 wild-type models also showed meaningful responses to the combination.
-
Animal Model:Immunodeficient nude mice[1]
-
Dosage:2, 5, 20 mg/kg
-
Administration:p.o.; single dose
-
Result:Inhibited IR-induced phospho-ATM (Ser1981) in a dose- and time-dependent manner, with 20 mg/kg producing the highest and most sustained inhibition (peaking at approximately 95% inhibition at 3 hours post-IR).
Reduced IR-induced phospho-Rad50 (Ser635) by up to 86% and induced statistically significant increases in apoptotic biomarker CC3 compared to IR alone.
Free brain concentrations peaked within 1 hour of dosing and correlated with ATM inhibition activity.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2089288-03-7
-
Appearance Solid
-
Molecular Weight 477.57
-
Formula C27H32FN5O2
-
Color White to off-white
-
SMILES
O=C(N1C(C)C)N(C)C2=C1C3=CC(C4=CC=C(OCCCN5CCCCC5)N=C4)=C(F)C=C3N=C2
-
Synonyms
AZD1390
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer. [Abstract]2025 Jun 13;10(1):185. PMID: 40506449
Elrelesertib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]
Immunoblot analysis was performed on cell lysates extracted from ANV5-OE cells at different time points after treatment with IR (2 Gy), IR/ENPP1i (5 µM), IR/ATMi (AZD1390: 5 µM), or triple therapy to detect the protein expression levels of γHA2X, PARP1, cleaved PARP1 (c-PARP), ENPP1, RAD51, GAPDH, and Tubulin.
Elrelesertib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]
The number of positive cells labeled with anti-γH2AX antibody was quantitatively assessed. Cells were incubated with ENPP1i (5 µM) and ATMi (AZD1390: 5 µM) for 24 h.
Elrelesertib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jun 13;10(1):185. [Abstract]
After orthotopic transplantation of OE-ANV5 cells, mice were treated with FD (6.2 Gy × 4) alone, or in combination with ENPP1i (6 mg/kg, twice daily), ATMi (AZD1390: 5 mg/kg, once daily), or triple therapy (n = 8 mice per group), and changes in tumor volume were observed.
-
Nat Nanotechnol
Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]2021 Jul;16(7):830-839. PMID: 33958764 -
Sci Adv
53BP1 orchestrates sequence feature of RAG targets to balance DNA repair outcomes during V(D)J recombination. [Abstract]2026 May 22;12(21):eaec2231. PMID: 42172328 -
EMBO J
DNA-PKcs and ATM modulate mitochondrial ADP-ATP exchange as an oxidative stress checkpoint mechanism. [Abstract]2023 Mar 15;42(6):e112094. PMID: 36727301
Elrelesertib purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]
HeLa cells expressing Flag‐tagged VDAC2 and V5‐tagged ANT2 were subjected to Co‐IP using anti‐Flag antibody and analyzed by western blot as indicated. ANT2, but not VDAC2, temporarily dissociated from DNA‐PKcs after treatment of 10 Gy IR. ATM knockdown and inhibition (AZD1390, 10 nM) disrupted the dissociation.
Elrelesertib purchased from MedChemExpress. Usage Cited in: EMBO J. 2023 Mar 15;42(6):e112094. [Abstract]
Primary mouse embryonic fibroblasts (MEF) RPE-1 were analyzed for ADP-ATP exchange activity at different time points (up to 16 hours) in response to 100 μM H₂O₂. The ATM inhibitor (AZD1390, 10 nM) was also included in the parallel analysis.
-
Int J Radiat Oncol Biol Phys
Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma. [Abstract]2023 Mar 15;115(4):957-971. PMID: 36368436 -
J Med Chem
Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors. [Abstract]2024 May 9;67(9):7620-7634. PMID: 38634707 -
-
CNS Neurosci Ther
AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury. [Abstract]2024 Apr;30(4):e14696. PMID: 38668740 -
Cancers (Basel)
Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer. [Abstract]2026 Jul 23;18(15):2381. PMID: 42588601 -
Shock
ATAXIA TELANGIECTASIA MUTATED PROTECTS AGAINST LIPOPOLYSACCARIDE-INDUCED BLOOD-BRAIN BARRIER DISRUPTION BY REGULATING ATK/DRP1-MEDIATED MITOCHONDRIAL HOMEOSTASIS. [Abstract]2023 Jul 1;60(1):100-109. PMID: 37141173 -
-
-
Solvent & Solubility
In Vitro:
DMSO : 5 mg/mL (10.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Fluorescent plasma-membrane potential dye assay
Fluorescent plasma-membrane potential dye assays measure changes in cell membrane potential using voltage-sensitive dyes whose fluorescence changes when cells depolarize or hyperpolarize. Anionic bis-oxonol dyes such as DiBAC4(3) enter depolarized cells more readily and show increased fluorescence after intracellular binding, while hyperpolarization reduces dye accumulation and fluorescence. FMP/FLIPR membrane-potential dyes are used for faster, homogeneous microplate assays of ion-channel or receptor-mediated membrane-potential changes.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (300 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0939 mL | 10.4697 mL | 20.9393 mL | 52.3483 mL |
| 5 mM | 0.4188 mL | 2.0939 mL | 4.1879 mL | 10.4697 mL | |
| 10 mM | 0.2094 mL | 1.0470 mL | 2.0939 mL | 5.2348 mL |